Novo Nordisk addresses safety concerns surrounding compounded versions of its weight-loss and diabetes drugs, including ...

Telehealth firm Hims & Hers Health said on Monday it plans to bring a generic version of Novo Nordisk's diabetes drug, liraglutide, to its platform in 2025.

Novo Nordisk maintained its sales growth momentum on booming sales of its weight loss and diabetes drugs, as it reported revenue and operating profit broadly in line with analysts’ expectations.

“The sales growth is driven by increasing demand for our GLP-1-based diabetes and obesity treatments, and we are serving more patients than ever before,” said president and CEO of Novo Nordisk ...

Novo Nordisk remains a sell due to increased competition and regulatory risks, despite its leadership in the diabetes and weight-loss markets. Hims & Hers anticipates selling a generic version of ...

Compounded versions of semaglutide, the active ingredient in approved diabetes and obesity drugs Ozempic and Wegovy, have ...

Wegovy manufacturer Ascendis Pharma has been tasked with supporting the development of a once-monthly GLP-1 drug.

The collaboration will focus on Novo Nordisk’s obesity and type 2 diabetes products, chief among them a once-monthly GLP-1RA to be developed as the joint venture’s lead candidate. Under the ...

While Novo Nordisk always focused on diabetes drugs, it did branch out beyond medicine. In the late 80s, young Lotte Knudsen was assigned to the enzyme team, which had the noble goal of making ...

The company said it plans to launch a generic version of a Novo Nordisk diabetes and weight-loss drug as early as 2025. Bank of America said Hims has “an opportunity to continue to drive user ...

Novo Nordisk (NYSE:NVO) (CSE:NOVOb) reported strong growth for the first nine months of 2024, with sales jumping by 23% in ...

But total group sales, which rose 21% to 71.3 billion crowns, came below the 72.3 billion crowns expected by analysts due to weaker-than-expected diabetes ... drugmaker Novo Nordisk and its ...